MNKD
NASDAQ · Biotechnology
Mannkind Corp
$3.44
-0.06 (-1.71%)
Open$3.56
Previous Close$3.50
Day High$3.57
Day Low$3.36
52W High$6.51
52W Low$2.23
Volume—
Avg Volume3.27M
Market Cap1.14B
P/E Ratio—
EPS$-0.14
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+818.9% upside
Current
$3.44
$3.44
Target
$31.61
$31.61
$20.51
$31.61 avg
$34.61
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 354.23M | 233.39M | 248.98M |
| Net Income | 5.96M | 3.54M | -49,454,944 |
| Profit Margin | 1.7% | 1.6% | -19.9% |
| EBITDA | 43.43M | 27.18M | -82,218,351 |
| Free Cash Flow | — | — | -29,596,680 |
| Rev Growth | +51.8% | +51.8% | +22.2% |
| Debt/Equity | 1.64 | 1.64 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |